Literature DB >> 11371414

Analysis of tumor necrosis factor-alpha, lymphotoxin-alpha, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis.

P Pantelidis1, G C Fanning, A U Wells, K I Welsh, R M Du Bois.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is characterized by chronic inflammation that is associated with structural damage of the lung and fibrosis. Although the etiology of IPF is unknown, it is likely to involve an interaction between environmental and multiple genetic components. Animal models of pulmonary fibrosis have shown that proinflammatory mediators are critical at both the inflammatory and fibrotic stages of the disease. Genetic variants exist in genes encoding proinflammatory mediators, as well as in genes encoding their receptors, which makes these genes candidates for the pathogenesis of IPF. In the present study, we examined 12 biallelic polymorphisms in the genes for tumor necrosis factor (TNF)-alpha (+488[G/A], -238[G/A], -308[G/A]), lymphotoxin (LT)-alpha (+720[C/A], +365[C/G], and +249[A/G], determining haplotypes LT-alpha1 to LT-alpha4), tumor necrosis factor-receptor 2 (TNF-RII) (gb:M32315: 676[T/G], 1663[A/G], 1668[T/G], 1690[C/T]), and interleukin- (IL)-6 (promoter -174[G/C], intron 4[A/G]). We also examined the haplotypes determined by the three biallelic polymorphisms in each of the TNF-alpha and LT-alpha genes. As compared with a normal control population, the IPF group showed no significant deviations in genotype, allele, or haplotype frequencies. Surprisingly, in the IPF population, but not in the control population, an increased frequency of cocarriage of the IL-6 intron 4G and the TNF-RII 1690C alleles was observed, despite the location of the two genes on different chromosomes. Moreover, using impairment of carbon monoxide transfer (DL(CO)) adjusted for duration of dyspnea as a marker of rapidity of disease progression, we found that the IL-6 intron 4GG genotype was the only genotype independently associated with lower DL(CO) levels. These findings, if independently confirmed, will be the first to suggest that disease progression in IPF may be linked to a particular genetic marker or to functional polymorphisms in other genes near that marker.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11371414     DOI: 10.1164/ajrccm.163.6.2006064

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  43 in total

Review 1.  Human Fibrosis: Is There Evidence for a Genetic Predisposition in Musculoskeletal Tissues?

Authors:  Louis Dagneaux; Aaron R Owen; Jacob W Bettencourt; Jonathan D Barlow; Peter C Amadio; Jean P Kocher; Mark E Morrey; Joaquin Sanchez-Sotelo; Daniel J Berry; Andre J van Wijnen; Matthew P Abdel
Journal:  J Arthroplasty       Date:  2020-06-04       Impact factor: 4.757

Review 2.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

3.  Interleukin-37 Attenuates Bleomycin-Induced Pulmonary Inflammation and Fibrosis in Mice.

Authors:  Yan Li; Qiaoyan Gao; Keye Xu; Xiao Peng; Xianli Yuan; Wenwen Jiang; Mingcai Li
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

4.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

5.  Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-β signaling.

Authors:  Gani Oruqaj; Srikanth Karnati; Vijith Vijayan; Lakshmi Kanth Kotarkonda; Eistine Boateng; Wenming Zhang; Clemens Ruppert; Andreas Günther; Wei Shi; Eveline Baumgart-Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

Review 6.  The genetic approach in pulmonary fibrosis: can it provide clues to this complex disease?

Authors:  William E Lawson; James E Loyd
Journal:  Proc Am Thorac Soc       Date:  2006-06

Review 7.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Authors:  Eric S White; Michael H Lazar; Victor J Thannickal
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

8.  Gene expression profiling and network analysis reveals lipid and steroid metabolism to be the most favored by TNFalpha in HepG2 cells.

Authors:  Amit K Pandey; Neha Munjal; Malabika Datta
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

9.  Role of host genetics in fibrosis.

Authors:  Georgina L Hold; Paraskevi Untiveros; Karin A Saunders; Emad M El-Omar
Journal:  Fibrogenesis Tissue Repair       Date:  2009-12-04

10.  Association of FcγRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression.

Authors:  Stylianos Bournazos; Jacob Grinfeld; Karen M Alexander; John T Murchison; William A Wallace; Pauline McFarlane; Nikhil Hirani; A John Simpson; Ian Dransfield; Simon P Hart
Journal:  BMC Pulm Med       Date:  2010-10-07       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.